Parallax Volatility Advisers
LCTX icon

Parallax Volatility Advisers’s Lineage Cell Therapeutics LCTX Stock Holding History

Parallax Volatility Advisers’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-24,200
Closed -$36.3K – 2686
2023
Q1 		$36.3K Buy
+24,200
New +$33.8K ﹤0.01% 2250

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parallax Volatility Advisers's LCTX Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Lineage Cell Therapeutics (LCTX) in Q1 2018, closing a stake of 13,778 shares — an estimated $26K sold.

Parallax Volatility Advisers first reported a position in LCTX in Q4 2017 and held it in 1 quarter. The position peaked at $26K in Q4 2017. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Lineage Cell Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 13,778 Lineage Cell Therapeutics shares in Q1 2018, an estimated $26K.
  • Parallax Volatility Advisers first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Lineage Cell Therapeutics position peaked at $26K in Q4 2017.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.